Amendment to Executive Employment Agreement between Qualigen Therapeutics, Inc. and Michael P. Poirier (January 13, 2023)
Qualigen Therapeutics, Inc. and executive Michael P. Poirier have agreed to a temporary amendment to Mr. Poirier's employment terms. Effective January 16, 2023, his annual base salary will be reduced by 20% to $460,000 as part of company-wide cost-cutting measures. This change was approved by the company's board of directors and is intended to help the company manage expenses and position itself for future success.
Exhibit 10.31
Amendment to Executive Employment Agreement with Michael P. Poirier, dated January 13, 2023
January 13, 2023
Dear Mr. Poirier:
As you know, on January 13, 2023, the board of directors of Qualigen Therapeutics, Inc. (the “Company”), as part of certain cost-cutting measures across the Company, approved a temporary 20% reduction to the base salaries of all executive officers of the Company.
To that end, effective as of January 16, 2023, your annual base salary will be reduced to $460,000.
We truly appreciate your loyalty, hard work and commitment to the Company. With your help and cooperation, I am confident that we will emerge stronger and hopeful the changes will allow us to effectively position the Company for future success.
Sincerely,
Christopher Lotz
VP and CFO of Qualigen Therapeutics, Inc.
